AM580_NN
,_,
a_DT
stable_JJ
benzoic_JJ
derivative_NN
of_IN
retinoic_JJ
acid_NN
,_,
has_VBZ
powerful_JJ
and_CC
selective_JJ
cyto-differentiating_JJ
effects_NNS
on_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
cells_NNS
._.

All-trans_JJ
retinoic_JJ
acid_NN
-LRB-_-LRB-
ATRA_NN
-RRB-_-RRB-
is_VBZ
successfully_RB
used_VBN
in_IN
the_DT
cyto-differentiating_JJ
treatment_NN
of_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
._.

Paradoxically_RB
,_,
APL_NN
cells_NNS
express_VBP
PML-RAR_NN
,_,
an_DT
aberrant_JJ
form_NN
of_IN
the_DT
retinoic_JJ
acid_NN
receptor_NN
type_NN
alpha_NN
-LRB-_-LRB-
RAR_NN
alpha_NN
-RRB-_-RRB-
derived_VBN
from_IN
the_DT
leukemia-specific_JJ
t_NN
-LRB-_-LRB-
15_CD
;_:
17_CD
-RRB-_-RRB-
chromosomal_JJ
translocation_NN
._.

We_PRP
show_VBP
here_RB
that_IN
AM580_NN
,_,
a_DT
stable_JJ
retinobenzoic_JJ
derivative_NN
originally_RB
synthesized_VBN
as_IN
a_DT
RAR_NN
alpha_NN
agonist_NN
,_,
is_VBZ
a_DT
powerful_JJ
inducer_NN
of_IN
granulocytic_JJ
maturation_NN
in_IN
NB4_NN
,_,
an_DT
APL-derived_JJ
cell_NN
line_NN
,_,
and_CC
in_IN
freshly_RB
isolated_VBN
APL_NN
blasts_NNS
._.

After_IN
treatment_NN
of_IN
APL_NN
cells_NNS
with_IN
AM580_NN
either_CC
alone_RB
or_CC
in_IN
combination_NN
with_IN
granulocyte_NN
colony-stimulating_JJ
factor_NN
-LRB-_-LRB-
G-CSF_NN
-RRB-_-RRB-
,_,
the_DT
compound_NN
induces_VBZ
granulocytic_JJ
maturation_NN
,_,
as_IN
assessed_VBN
by_IN
determination_NN
of_IN
the_DT
levels_NNS
of_IN
leukocyte_NN
alkaline_NN
phosphatase_NN
,_,
CD11b_NN
,_,
CD33_NN
,_,
and_CC
G-CSF_NN
receptor_NN
mRNA_NN
,_,
at_IN
concentrations_NNS
that_WDT
are_VBP
10_CD
-_CD
to_TO
100-fold_RB
lower_JJR
than_IN
those_DT
of_IN
ATRA_NN
necessary_JJ
to_TO
produce_VB
similar_JJ
effects_NNS
._.

By_IN
contrast_NN
,_,
AM580_NN
is_VBZ
not_RB
effective_JJ
as_IN
ATRA_NN
in_IN
modulating_VBG
the_DT
expression_NN
of_IN
these_DT
differentiation_NN
markers_NNS
in_IN
the_DT
HL-60_NN
cell_NN
line_NN
and_CC
in_IN
freshly_RB
isolated_VBN
granulocytes_NNS
obtained_VBN
from_IN
the_DT
peripheral_JJ
blood_NN
of_IN
chronic_JJ
myelogenous_JJ
leukemia_NN
patients_NNS
during_IN
the_DT
stable_JJ
phase_NN
of_IN
the_DT
disease_NN
._.

In_IN
NB4_NN
cells_NNS
,_,
two_CD
other_JJ
synthetic_JJ
nonselective_JJ
RAR_NN
ligands_NNS
are_VBP
capable_JJ
of_IN
inducing_VBG
LAP_NN
as_RB
much_JJ
as_IN
AM580_NN
,_,
whereas_IN
RAR_NN
beta_NN
-_:
or_CC
RAR_NN
gamma-specific_JJ
ligands_NNS
are_VBP
totally_RB
ineffective_JJ
._.

These_DT
results_NNS
show_VBP
that_IN
AM580_NN
is_VBZ
more_RBR
powerful_JJ
than_IN
ATRA_NN
in_IN
modulating_VBG
the_DT
expression_NN
of_IN
differentiation_NN
antigens_NNS
only_RB
in_IN
cells_NNS
in_IN
which_WDT
PML-RAR_NN
is_VBZ
present_JJ
._.

Binding_VBG
experiments_NNS
,_,
using_VBG
COS-7_NN
cells_NNS
transiently_RB
transfected_VBN
with_IN
PML-RAR_NN
and_CC
the_DT
normal_JJ
RAR_NN
alpha_NN
,_,
show_VBP
that_IN
AM580_NN
has_VBZ
a_DT
lower_JJR
affinity_NN
than_IN
ATRA_NN
for_IN
both_DT
receptors_NNS
._.

However_RB
,_,
in_IN
the_DT
presence_NN
of_IN
PML-RAR_NN
,_,
the_DT
synthetic_JJ
retinoid_NN
is_VBZ
a_DT
much_RB
better_JJR
transactivator_NN
of_IN
retinoic_JJ
acid-responsive_JJ
element-containing_JJ
promoters_NNS
than_IN
the_DT
natural_JJ
retinoid_NN
,_,
whereas_IN
,_,
in_IN
the_DT
presence_NN
of_IN
RAR_NN
alpha_NN
,_,
AM580_NN
and_CC
ATRA_NN
have_VBP
similar_JJ
activity_NN
._.

This_DT
may_MD
explain_VB
the_DT
strong_JJ
cyto-differentiating_JJ
potential_NN
of_IN
AM580_NN
in_IN
PML-RAR-containing_JJ
leukemic_JJ
cells_NNS
._.

